Dr. Snyder is interested in using targeted therapies to help patients with complex vascular anomalies. Dr. Snyder trained in Pediatric Hematology and Oncology at the Johns Hopkins and National Institutes Fellowship Program. She subsequently served as a medical officer at the Food and Drug Administration in the Center for Drug Evaluation and Research prior to being recruited to Vanderbilt University in Nashville, Tennessee.

While at Vanderbilt, Dr. Snyder developed an interest in complex vascular anomalies and was a member of Monroe Carell, Jr. Children’s Hospital at Vanderbilt Vascular Anomalies Multi-disciplinary program and served as an investigator contributing to the Agency for Healthcare Research and Quality Evidence Based Practice Center’s Infantile Hemangioma Comparative Effectiveness Review. She was subsequently recruited to Helen DeVos Children’s Hospital where she helped establish a Multi-disciplinary Vascular Anomalies team to better care for children with these conditions.

Dr. Snyder arrived at Children’s Hospital of Philadelphia in 2019.  She has assumed a number of leadership roles at CHOP including interim director of CHOP’s Frontier Complex Vascular Anomalies Program and CHOP investigator to the Consortium of iNvestigators of Vascular AnomalieS (CaNVAS).  In addition, she has a number of expanded access investigational new drug applications to treat patients with vascular anomaly conditions with novel targeted agents for these indications. She is interested in applying targeted agents, developed for oncology indications, to the dysregulated signaling that drives these vascular anomalies.

Dr. Snyder is nationally recognized for her work, is the immediate past vice-chair for education of the American Society of Pediatric Hematology Oncology Vascular Anomalies Special Interest Group (ASPHO-VA SIG), current ASPHO-VA SIG education chair, and ASPHO-VA SIG steering committee member. She is a guest editor of a collection of manuscripts related to the care of patients with vascular anomalies, and she has authored various articles and book chapters on vascular anomaly conditions.

MD, Michigan State University College of Human Medicine

Internship (Pediatrics) University of Michigan Department of Pediatrics Residency Program, C.S. Mott Children's Hospital

Residency (Pediatrics) University of Michigan Department of Pediatrics Residency Program, C.S. Mott Children's Hospital

Fellowship (Pediatric Hematology/Oncology) Johns Hopkins University/National Cancer Institute

Board Certification:

Pediatric Hematology/Oncology
Pediatrics

Attending Physician

Interim director of Children’s Hospital of Philadelphia Frontier’s Program in Complex Vascular Anomalies

International Society for the Study of Vascular Anomalies, 2018-

Children's Oncology Group, 2012-

Consortium of iNvestigators of Vascular AnomalieS (CaNVAS), Inaugural Member, 2018-

American Society of Pediatric Hematology, 2006-

Vascular Anomalies Special Interest Group, Education Chair, 2019-2020

Vascular Anomalies Special Interest Group, Education Vice Chair, 2016-2018

Vascular Anomalies Special Interest Group, Steering Committee, 2013-

Vascular Anomalies Special Interest Group, 2013-

Consultant of the Month, Spectrum Health Emergency Department Helen DeVos Children's Hospital, 2018

Nashville's Best Doctors, 2013, 2014

Group Recognition Award as a member of the Division of Drug Oncology Products, Food and Drug Administration, 2011

Fellow/Awardee, Washington D.C. Clinical Research Training Consortium, 2007-2009

Fellows Award for Research Excellence, National Institutes of Health, 2006